Fepixnebart
Based on 1 publication(s) in Google Scholar
Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 96.46%
- No. CAS: 2489584-93-0
- Peso molecular:145.44 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Fepixnebart
MoreVer todos los productos específicos de isoformas EGFR
More
Actividad biológica
Human IgG4 kappa
Human
TGFA
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 Balb/3T3 cells with Fepixnebart (HY-P990071, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
No. CAS 2489584-93-0
-
Appearance Liquid
-
Peso molecular 145.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Fepixnebart]
-
Synonyms
LY-3016859
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
NPJ Breast Cancer
TGF-α/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer. [Abstract]2026 Apr 3;12(1):52. PMID: 41932901
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Boyles JS, et al. Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody. Protein Sci. 2016 Nov;25(11):2028-2036. [Content Brief]
[2]. James DE, et al. Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain. Clin Pharmacokinet. 2025 May;64(5):757-767. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)